A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis
ID Number 09-0007Principal Investigator(s)
Department(s) or Division(s)
The purpose of this study is to find out how effective the study medication, Fingolimod (FTY720) is in delaying disability in patients with Primary Progressive Multiple Sclerosis (PPMS).
Recruiting Patients: No